**Core tip:** Despite the increasing incidence of non-alcoholic fatty liver disease (NAFLD) and NAFLD related hepatocellular carcinoma (HCC) in developed countries, information related with the burden of NAFLD-HCC in developing countries as those in South America is lacking. In this multicenter cohort study from Argentina including patients with HCC, while HCV and alcoholic related cirrhosis were the most frequent causes of HCC between 2009 and 2016, NAFLD-HCC had a 6-fold increased during the same period. This changing scenario was observed without precluding any specific etiology of liver disease. NAFLD might become one of the first HCC related causes in the coming decades; an issue to be consider with effective prevention strategies.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the second leading cause of cancer related death worldwide and the main cause of death among patients with cirrhosis\[[@B1],[@B2]\]. The incidence of HCC varies according to geographic location, closely linked to the prevalence of chronic hepatitis C (HCV) or B virus (HBV) infections as well as the prevalence of alcoholic liver disease.

With the advent of new direct antiviral drugs (DAAs) for HCV treatment, epidemiological changes have been reported in the natural history of liver disease\[[@B3]\]. First, the improvement of decompensated cirrhotic patients, the consequence and the increasing rate of delisting from liver transplantation (LT) waitlist after eradication of HCV. On the other hand, a lower wait-listing ratio of patients with HCV decompensated cirrhosis has been observed\[[@B3]\]. However, the proportion of patients listed for LT with HCC has been increased during the era of DAAs\[[@B4]\].

This increasing incidence of HCC has been attributed in developed countries due to a stepwise increase in the incidence of non-alcoholic fatty liver disease (NAFLD), recognized as an emergent cause of end stage liver disease and HCC\[[@B4],[@B5]\]. NAFLD is the expression of a pandemic disease, which is associated with the metabolic syndrome, obesity and type 2 diabetes. Indeed, it is estimated that during the next 20 years, non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, will constitute the most frequent cause of cirrhosis and HCC in developed countries\[[@B6]\].

However, HCC epidemiological reports from developing areas, including South America, have been heterogeneous\[[@B7]-[@B14]\]. Furthermore, no studies have tackled the issue of changing trends in etiologies of HCC over time. Our present aim was to evaluate changes in etiology of HCC in Argentina during the last seven years, focusing on two aspects, the potential changes associated with DAA's era of HCV treatment, as well as changes associated with NAFLD-HCC.

MATERIALS AND METHODS
=====================

This longitudinal observational cohort study was conducted between January 1 2009 and January 1 2016 in 14 regional hospitals from Argentina. Sites were instructed to enroll all eligible patients on a sequential basis and data to be recorded from medical charts into a web-based electronic system.

A cohort of consecutive adult patients (\> 17 years of age) with newly diagnosed HCC was included. Criteria for inclusion required patients to have newly diagnosed HCC either by pathological criteria or imaging evaluation as recommended by international guidelines\[[@B15],[@B16]\].

Etiologies of HCC considering the primary diagnosis of liver disease included HCV (anti HCV positivity), HBV (hepatitis B surface antigen positivity), alcoholic liver disease (alcohol intake exceeding 30 g), NAFLD, cryptogenic cirrhosis (CC), cholestatic liver diseases (*i.e*., primary biliary cholangitis, primary and secondary sclerosing cholangitis), autoimmune hepatitis and other causes including metabolic diseases or miscellaneous causes (*e.g*., hereditary hemochromatosis, Wilson disease, toxic liver disease).

NAFLD diagnosis was achieved on histological ground or clinically according to international guidelines\[[@B17]\]. Patients were classified as presenting clinical NAFLD provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound (US) and alcohol consumption was excluded (30 g for men and 20 g women). Histological NAFLD was defined by an excessive hepatic fat accumulation associated with insulin resistance and the presence of \> 5% of steatosis in liver biopsy. NAFLD included non-alcoholic fatty liver and NASH.

Baseline patient and tumor characteristics were recorded at HCC diagnosis including patients demographics, previous US surveillance, performance status (Eastern Cooperative Oncology Group, ECOG grade 0-4)\[[@B18]\], liver fibrosis stage (I-IV) assessed by liver biopsy elastography, other non-invasive measurements or by clinical data (presence of esophageal varices or ascites or splenomegaly \> 120 mm diameter, or features related to portal hypertension), Child Pugh score and laboratory variables. Serum alpha-fetoprotein (AFP) levels at diagnosis were categorized in three cut-off values: ≤ 100 ng/mL, 101-1000 ng/mL and \> 1000 ng/mL\[[@B19]\].

Specific major co-morbidities for each subject were also registered including: diabetes mellitus, severe chronic pulmonary disease, coronary heart disease and congestive heart disease, previous ischemic or hemorrhagic stroke, peripheral vascular disease, chronic kidney failure (glomerular filtration rate \< 30 mL/min) and non-HCC cancer.

Tumor characteristics and treatments performed during follow-up were also registered. Computed tomography (CT) or magnetic resonance images (MRI) were included to assess tumor burden, which was classified according to Barcelona Clinic Liver Cancer staging (BCLC criteria)\[[@B16]\].

Study end-points
----------------

Our study focused on changing trends of HCC etiologies at different periods from 2009 to 2016. A stratified per-etiology analysis and per Liver Transplant (LT) and non-LT centers was performed. Complete patient follow-up was assessed in all included subjects from HCC diagnosis until death or last medical visit.

All procedures followed were in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines\[[@B20]\]. This study was approved by the Austral University School of Medicine and by all 14 centers; complied with the ethical standards (institutional and national) and with Helsinki Declaration of 1975, as revised in 2008. Patient consent was obtained in all subjects included.

Statistical analysis
--------------------

Institutional clinical research committee reviewed the statistical methods of this study. Categorical data were compared using Fisher's exact test (2-tailed) or χ^2^ test. Continuous variables were compared with Student's *t*-test or Mann-Whitney *U* test according to their distribution, respectively. For survival analysis, Cox regression multivariate analysis estimating hazard ratios (HR) and 95%CI for baseline variables related with 5-year mortality was performed. Confounding effect was defined when more than 20% of change in the crude HR. Kaplan Meier survival curves were compared using the log-rank test (Mantel-Cox) and adjustment of each final model was evaluated with proportional hazards through graphic and statistical evaluation (Schoenfeld residual test). Calibration was assessed by comparison of observed and predicted curves and evaluation of the goodness of fit of the model by Harrell's c-statistic index. Collected data was analyzed using STATA 10.0.

RESULTS
=======

A total of 708 consecutive adult patients with newly diagnosed HCC from 14 centers were included. Out of 14 hospitals, 6 were LT centers, which contributed with the follow-up of 484 patients (68.4% of the study cohort).

Baseline patients and tumor characteristics
-------------------------------------------

Table [1](#T1){ref-type="table"} describes the baseline patients' characteristics. Non-cirrhotic patients accounted for 12.6% of the included cohort (*n* = 89). Overall prevalence of diabetes mellitus (DBT) was 27.7% (Table [1](#T1){ref-type="table"}).

###### 

Patients' baseline characteristics

  **Variable**                       ***P* values**
  ---------------------------------- ----------------------------------
  Age, yr (± SD)                     62 ± 10
  Male gender, *n* (%)               537 (75.9)
  Non-cirrhotic liver, *n* (%)       89 (12.6)
  Child Pugh A/B/C, *n* (%)          352 (49.7)/238 (33.6)/118 (16.7)
  Comorbidities, *n* (%)             299 (42.2)
  Diabetes mellitus, *n (%)*         196 (27.7)
  Ascites, *n* (%)                   253 (35.7)
  Mild                               144 (20.3)
  Moderate-severe                    109 (15.4)
  Encephalopathy, *n* (%)            147 (20.8)
  Grade I-II                         137 (19.3)
  Grade III-IV                       10 (1.4)
  Esophageal varices, *n* (%)        394 (56.7)
  ECOG 0-2/3-4, *n* (%)              637 (89.9)/71 (10.1)
  Median HCC number, (IQR)           1.0 (1.0-2.0)
  Largest HCC diameter, mm (IQR)     53 ± 37
  Within Milan, *n* (%)              334 (46.9)
  Bilobar involvement, *n* (%)       159 (22.1)
  Diffuse HCC pattern, *n* (%)       28 (3.9)
  Median AFP, ng/mL (IQR)            23.0 (5.0-337.0)
  ≤ 100 ng/mL, *n* (%)               476 (66.3)
  101-1000 ng/mL, *n* (%)            128 (17.7)
  \> 1000 ng/mL, *n* (%)             115 (16.0)
  Tumor vascular invasion, *n* (%)   74 (10.4)
  Extrahepatic disease, *n* (%)      48 (6.8)

ECOG: Eastern Cooperative Oncology Group; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein.

Overall, HCV was the most frequent cause of underlying liver disease. Etiology of HCC in cirrhotic patients was as follows: 37% HCV infection (*n* = 262), 20.8% alcoholic liver disease (*n* = 147), 11.4% NAFLD (*n* = 81), 9.6% cryptogenic cirrhosis/liver disease (CC, *n* = 68), 5.4% HBV infection (*n* = 38), 2.2% of cholestatic disease and autoimmune hepatitis (*n* = 16), and 9.9% other causes (*n* = 60) (Table [2](#T2){ref-type="table"}). Most frequent HCV genotypes (G) were G1b (*n* = 88), followed by G1a (*n* = 47), G3 (*n* = 27), G2 (*n* = 8) and G4 (*n* = 2) (Figure [1](#F1){ref-type="fig"}).

![Etiologies oh hepatocellular carcinoma in the overall cohort and hepatitis C virus genotypes. HCV was the main cause of liver disease related with hepatocellular carcinoma including cirrhotic and non-cirrhotic patients. Distribution of known HCV genotypes (G) showed that G1b was the most frequent (*n* = 88), followed by G1a (*n* = 47), G3 (*n* = 27), G2 (*n* = 8) and G4 (*n* = 2). HCV: Hepatitis C virus.](WJH-10-41-g001){#F1}

###### 

Underlying etiologies of liver disease per year (frequencies)

              **HCV**      **HBV**    **Alcohol**   **NASH**    **CC**      **Cholestasis**   **AI**    **Other[1](#T2FN1){ref-type="table-fn"}**   **Total**
  ----------- ------------ ---------- ------------- ----------- ----------- ----------------- --------- ------------------------------------------- -----------
  2009        24 (34.3)    7 (10.0)   18 (25.7)     3 (4.3)     9 (12.9)    0                 0         9 (12.9)                                    70
  2010        51 (48.6)    5 (4.8)    16 (15.2)     5 (4.8)     12 (11.4)   3 (2.9)           1 (0.9)   12 (11.5)                                   105
  2011        34 (35.6)    5 (5.3)    26 (27.4)     10 (10.5)   9 (9.5)     1 (1.0)           1 (1.0)   7 (6.4)                                     95
  2012        43 (38.0)    5 (4.4)    21 (18.6)     14 (12.4)   10 (8.8)    3 (2.6)           0         5 (8.0)                                     113
  2013        43 (33.1)    9 (6.9)    24 (18.5)     14 (10.8)   17 (13.1)   2 (1.5)           1 (0.8)   13 (10.0)                                   130
  2014        43 (36.7)    4 (3.4)    22 (18.8)     15 (12.8)   9 (7.7)     3 (2.6)           0         16 (13.7)                                   117
  2015        24 (30.8)    3 (3.8)    20 (25.6)     20 (25.6)   2 (2.6)     1 (1.3)           0         4 (5.2)                                     78
  Total (%)   262 (37.0)   38 (5.4)   147 (20.8)    81 (11.4)   68 (9.6)    13 (1.8)          3 (0.4)   60 (9.9)                                    708

Other causes of cirrhosis, Hemochromatosis. NASH: Non-alcoholic steatohepatitis; AI: Autoimmune; CC: Cryptogenic cirrhosis; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Etiology of HCC among non-cirrhotic patients included cryptogenic liver disease in 52.8% (*n* = 47), chronic HCV infection in 21.3% (*n* = 19), NAFLD in 10.1% (*n* = 9), chronic HBV infection in 9.0% (*n* = 8), altered iron metabolism in 4.5% (*n* = 4) and chronic alcohol consumption in 2 patients.

At HCC diagnosis, 4.2% (*n* = 30), 43.1% (*n* = 305), 21.3% (*n* = 151), 9.5% (*n* = 67) and 21.9% (*n* = 155) of the patients were within BCLC 0, A, B, C and D stages, respectively. Median serum AFP was 23.0 ng/mL (IQR 5.0; 337 ng/mL, Table [1](#T1){ref-type="table"}).

Etiologies of HCC stratified by periods of time
-----------------------------------------------

Changes over time for each HCC etiology were analyzed in order to observe any epidemiological changes during the entire period. HCV related HCC was the most frequent etiology along the whole observation period. No significant changes were observed in the proportion of HCV-HCC (Table [2](#T2){ref-type="table"}). The second most frequent cause of HCC was alcoholic liver disease, remaining stable during the observation period. On the other hand, a striking 6-fold increase in the proportion of HCC-NAFLD cases was observed since 2009 to 2016 (4.3% *vs* 25.6%; *P* \< 0.0001). Moreover, NAFLD represented the second cause of HCC in 2015 together with alcoholic liver disease (Table [2](#T2){ref-type="table"}).

We further considered patients with cryptogenic cirrhosis and DBT (*n* = 22/68) as potentially NAFLD. This new group was merged with NAFLD accounting for 14.5% (*n* = 103) of the entire cohort. Its incidence increased from 8.6% in 2009 to 16.2% in 2014 and 25.6% in 2016, respectively (*P* = 0.014). Prevalence of DBT was similar between HCC cirrhotic and non-cirrhotic patients (23.2% *vs* 28.2%; *P* = 0.38).

Comparative analysis between NAFLD and non-NAFLD HCC patients
-------------------------------------------------------------

A comparative analysis between NAFLD and non-NAFLD-HCC was performed. Mean age was similar in both groups. Only a small proportion of patients were non-cirrhotic (8.6% NAFLD *vs* 9.9% non-NAFLD; *P =* 0.72). There were no significant differences regarding Child Pugh score, MELD score and presence of clinically significant portal hypertension (Table [3](#T3){ref-type="table"}).

###### 

Comparative analysis between non alcoholic fatty liver disease and other than non alcoholic fatty liver disease

  **Variable**                     **NAFLD *n* = 81 (11.4%)**    **Non-NAFLD *n* = 627 (88.6%)**    ***P* value**
  -------------------------------- ----------------------------- ---------------------------------- ---------------
  Age, yr (± SD)                   63 ± 8                        62 ± 4                             0.39
  Gender, male, *n* (%)            68 (83.9)                     469 (74.9)                         0.06
  Non-cirrhotic liver, *n* (%)     7 (8.6)                       62 (9.9)                           0.72
  Child Pugh A/B/C, *n* (%)        41 (50.6)/32 (39.5)/8 (9.9)   311 (49.6)/206 (32.8)/110 (17.5)   0.15
  Comorbidities, *n* (%)           60 (74.1)                     239 (38.1)                         \< 0.0001
  Diabetes mellitus, *n* (%)       50 (61.7)                     146 (23.3)                         \< 0.0001
  Median AFP level, ng/mL          6.6 (4-380)                   26 (5.3-332)                       0.017
  AFP \> 1000 ng/mL, *n* (%)       9 (12.0)                      97 (16.1)                          0.34
  Ascites, *n* (%)                                                                                  
  Mild                             17 (21.0)                     127 (20.3)                         0.7
  Moderate-severe                  10 (12.3)                     99 (15.8)                          0.7
  Encephalopathy, *n* (%)                                                                           
  Grade I-II                       18 (22.2)                     119 (19.0)                         0.2
  Grade III-IV                     3 (3.7)                       7 (1.1)                            0.2
  Esophageal varices, *n* (%)      50 (63.3)                     344 (55.8)                         0.5
  ECOG 0-2, *n* (%)                73 (90.1)                     564 (89.9)                         0.96
  Median HCC number, (IQR)         1 (1-2)                       1 (1-2)                            0.38
  Largest HCC diameter, mm (IQR)   55 ± 37                       52 ± 37                            0.51
  Within Milan, *n* (%)            38 (46.9)                     295 (47.0)                         0.98
  Bilobar involvement, *n* (%)     16 (19.7)                     142 (22.7)                         0.82
  Diffuse HCC pattern, *n* (%)     3 (3.7)                       20 (3.2)                           0.82

AFP: Alpha-fetoprotein; MELD: Model for end stage liver disease; AFLD: Alcoholic fatty liver disease; Non-NAFLD: Other than NAFLD (includes all other etiologies).

Comorbidities were most frequently observed in the NAFLD group, particularly there was a higher prevalence of diabetes mellitus (DBT) (61.7% *vs* non-NAFLD 23.3%; *P* \< 0.0001). When a stratified analysis was performed comparing the prevalence of DBT, there were no changes observed ranging from 8.9% in 2009 to 17.3% in 2012 (*P* = 0.89). As previously shown, the increasing proportion of NAFLD in the overall cohort was not in parallel with an increasing prevalence of DBT.

Regarding HCC burden, there were no significant differences with previous surveillance (NAFLD 59.5% *vs* non-NAFLD 57.9%; *P* = 0.81) and BCLC staging at HCC diagnosis. Median AFP was lower in the NAFLD-HCC when compared to non-NAFLD group (6.6 ng/mL *vs* 26 ng/mL; *P* = 0.02) (Figure [2](#F2){ref-type="fig"}).

![Comparative analysis regarding hepatocellular carcinoma previous surveillance and Barcelona Clinic Liver Cancer staging at diagnosis between non alcoholic fatty liver disease and other etiologies of liver disease. NAFLD: Non-alcoholic fatty liver disease: Non-NAFLD: Other than NAFLD (includes all other etiologies).](WJH-10-41-g002){#F2}

Etiology of HCC in non-liver transplant vs liver transplant centers
-------------------------------------------------------------------

Among LT centers, the main etiology of HCC during 2009 was HCV, remaining stable over the years, becoming the second cause of HCC in 2015. Furthermore, the main cause of HCC during 2015 was NAFLD, showing 6-fold increase from 2009 to 2014 and 2015 (5.8% *vs* 13.9% *vs* 36.9%, respectively; *P* \< 0.0001). Alcoholic liver disease was the second overall cause of HCC, which was unchanged since 2009 among the different periods.

In non-transplant centers, HCV was the most frequent cause of HCC during all analyzed periods, followed by alcoholic liver disease. No significant changes in the proportion of patients with HCV or alcoholic liver disease were observed in this group. An increasing number of NAFLD-HCC cases were observed, which was lower than that observed in LT centers (LT centers 5.8% to 36.9%; *P* \< 0.0001 *vs* non-LT centers 0% to 9%; *P* = NS).

Etiologies and impact on patient survival
-----------------------------------------

Both uni and multivariate Cox regression analysis were performed as shown on Table [4](#T4){ref-type="table"} evaluating baseline patient and HCC characteristics associated with worse survival. Neither the presence of comorbidities (HR 1.08; CI 0.86; 1.37) nor DBT were related to mortality (HR 0.83; CI 0.63; 1.08). When considering different HCC etiologies, neither NAFLD nor viral etiologies presented higher mortality rates during the follow-up (Figure [3](#F3){ref-type="fig"}).

![Comparative survival between non alcoholic fatty liver disease and other etiologies of liver disease. NAFLD: Non-alcoholic fatty liver disease; Non-NAFLD: Other than NAFLD (includes all other etiologies).](WJH-10-41-g003){#F3}

###### 

Baseline pre-treatment variables associated with 5-year mortality, univariate cox regression

  **Variable**                                 **5-yr mortality rate, (%)**   **Hazard ratio (95%CI)**   **P value**
  -------------------------------------------- ------------------------------ -------------------------- -------------
  Age (yr)                                                                    1.02 (1.01; 1.04)          \< 0.0001
  Gender: male (*n =* 537)                     42.7                           1.08 (0.83; 1.42)          0.58
  Female (*n =* 170)                           42.3                                                      
  Comorbidity                                                                                            
  Yes (*n =* 299)                              45.1                           1.08 (0.86; 1.37)          0.49
  No (*n =* 409)                               40.6                                                      
  Diabetes mellitus                                                                                      
  Yes (*n =* 196)                              38.8                           0.83 (0.63; 1.08)          0.17
  No (*n =* 512)                               44                                                        
  NAFLD                                                                                                  
  Yes (*n =* 81)                               35.9                           1.16 (0.81; 1.69)          0.41
  No (*n =* 627)                               56.9                                                      
  ECOG 0-2                                                                                               
  Yes (*n =* 637)                              37.9                           0.19 (0.14; 0.26)          0.0001
  No (*n =* 71)                                84.5                                                      
  BCLC 0-A                                                                                               
  Yes (*n =* 335)                              26                             0.29 (0.23; 0.38)          0.0001
  No (*n =* 373)                               57.4                                                      
  Cirrhosis                                                                                              
  Yes (*n =* 639)                              42.9                                                      
  No (*n =* 69)                                39.1                           0.86 (0.58; 1.28)          0.45
  Child Pugh                                                                                             
  A (*n =* 352)                                34.5                           \-                         
  B (*n =* 238)                                41.6                           1.38 (1.06; 1.83)          0.019
  C (*n =* 118)                                68.6                           3.23 (2.41; 4.34)          0.0001
  Clinically significant portal hypertension                                                             
  Yes (*n =* 484)                              40.2                           1.22 (0.94; 1.57)          0.13
  No (*n =* 224)                               43.7                                                      
  AFP \> 1000 ng/mL                                                                                      
  Yes (*n =* 106)                              64.1                           3.09 (2.31; 4.15)          0.0001
  No (*n =* 569)                               39.5                                                      
  Tumor vascular invasion                                                                                
  Yes (*n =* 74)                               77                             4.74 (3.48; 6.44)          0.0001
  No (*n =* 634)                               38.5                                                      
  Extrahepatic tumor disease                                                                             
  Yes (*n =* 48)                               70.8                           3.29 (2.25; 4.81)          0.0001
  No (*n =* 660)                               40.5                                                      

Normal Values: Alpha-fetoprotein 0.6-4.4 ng/mL. AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; ECOG: Eastern cooperative oncology group; HCC: Hepatocellular carcinoma; LT: Liver transplantation; WL: Waiting list; NAFLD: Non-alcoholic fatty liver disease.

On the multivariate model, independent variables associated with death were age HR 1.03 (CI 1.01; 1.04), BCLC 0-A stages *vs* non 0-A stages HR 0.50 (CI 0.37; 0.68), Child Pugh B or C *vs* A HR 1.54 (CI 1.61; 2.05), HR 2.59 (CI 1.84; 3.66), respectively; AFP \> 1000 ng/mL at HCC diagnosis HR 2.09 (CI: 1.52; 2.87) and HCC vascular invasion HR 2.83 (CI: 1.75; 3.53) (Table [5](#T5){ref-type="table"}).

###### 

Multivariate cox regression analysis of risk factors associated with 5-year mortality

  **Variable**                                   **HR**   **95%CI**    ***P* value**
  ---------------------------------------------- -------- ------------ ---------------
  Age                                            1.03     1.01; 1.04   \< 0.0001
  BCLC 0-A                                       0.50     0.37; 0.68   \< 0.0001
  Child Pugh B[1](#T5FN1){ref-type="table-fn"}   1.54     1.61; 2.05   0.003
  Child Pugh C[1](#T5FN1){ref-type="table-fn"}   2.59     1.84; 3.66   \< 0.0001
  AFP \> 1000 ng/mL                              2.09     1.52; 2.87   \< 0.0001
  Tumor vascular invasion                        2.84     1.75; 3.53   \< 0.0001

Compared to Child Pugh A, Harrell's concordance statistic was 0.76.

DISCUSSION
==========

To the best of our knowledge this is the first multicenter cohort study from a South American country evaluating longitudinal changes in etiologies of HCC. This changing etiologic scenario documented in developed countries is replicated in developing ones\[[@B4],[@B5]\]. The documented increase in NAFLD-HCC in our study entails itself a challenging impact on Public Health worth to be considered in developing countries. HCV infection was the main etiology of HCC throughout the entire observation period, including the last two years, at which time DAA's therapy was available in Argentina (since 2014). Second, as reported in other regions of the world, fatty liver disease was observed as an increasing cause of HCC. The prevalence of DBT was significantly higher in NAFLD-HCC when compared to non-NAFLD patients. Finally, NAFLD-HCC was not associated with a higher mortality rate.

In a recently published multicenter Latin American retrospective cohort study, the main etiologies of HCC were HCV in almost half of the cases, followed by alcoholic liver disease, HBV infection and NAFLD in nine percent\[[@B8]\]. Another multicenter study from this region including HCC LT patients showed that the most frequent cause of HCC was HBV\[[@B9]\]. This discrepancies show that the reported HCC etiology largely reflects country-to-country epidemiological differences. Whereas in Brazil the main etiology has been shown to be HBV, in Argentina the main HCC etiology has been associated with HCV followed by alcoholic liver disease\[[@B9],[@B10],[@B21]\]. However, no previous studies have evaluated etiologic changes longitudinally.

It is already known that in developed countries, a high-fat diet leads to obesity, insulin resistance, metabolic syndrome and type 2 DBT. Unbalanced hyper-caloric diets, as well as an increasing consumption of sugar containing beverages might lead to a profound Public Health intervention. These socioeconomically changes have been occurring not only in developed but also in developing regions worldwide.

NAFLD has been related to an increasing rate of overall cardiovascular morbid-mortality\[[@B6]\]. Consequently, NAFLD will become responsible of an increase in medical resource use in the next years that demands specific health prevention programs focusing on diet and exercise in order to avoid not only liver but also cardiovascular disease development. As previously mentioned, a six-fold increase in NAFLD from 2009 to 2015 was observed in our cohort, mainly in LT centers whereas alcoholic liver disease was a leading cause of HCC in non-LT centers. This finding has been observed in Argentina by other authors\[[@B10]\].

DBT leads to fibrosis progression, cirrhosis and HCC\[[@B6],[@B22],[@B23]\]. We observed that the increasing prevalence of NAFLD-HCC was not in parallel with the increasing prevalence of DBT over the years. When we included as "potentially NAFLD" those patients with cryptogenic cirrhosis with DBT, a similar 6-fold increase since 2009 to 2015 was observed. Alternatively, we did not considered obese patients with cryptogenic cirrhosis as probable NAFLD as reported by other authors\[[@B24]\]. In our series, body mass index was not recorded. However, we performed a sub analysis considering cryptogenic/DBT patients and NAFLD. Our epidemiological results are in line with that from developed countries, suggesting that NAFLD would have a major Public Health implication in the upcoming years.

Third, from a comparative and specific intergroup variability, there were no differences between non-NAFLD and NAFLD-HCC patients, except from a higher prevalence of diabetes mellitus and lower AFP values in NAFLD-HCC group. Interestingly, higher AFP values were described in other studies in this group of patients in comparison to other etiologies\[[@B22]\]. However, this significant difference did not impact on patient survival, although AFP \> 1000 ng/mL at HCC diagnosis was an independent predictor of worse survival in the multivariate Cox regression analysis. There were no major differences in HCC tumor burden between NAFLD and non-NAFLD-HCC. Heterogeneous data has been published regarding this topic. Some studies described tumor differences whereas others did not\[[@B25],[@B26]\].

We acknowledge limitations of cohort studies with no control group, in which several factors might be biased. However, a strict revision of the data was centrally requested, investigators who performed the final analysis did not participate in the data collection to avoid differential outcome assessment on exposure and a complete follow-up and outcome assessment was performed in all patients included. Second, the definition of NAFLD was mainly based on clinical assessment. The lack of histological evaluation of NAFLD and NASH in most of the patients might have biased the results. However, this clinical definition is accepted worldwide by international guidelines\[[@B17]\]. Third, an important information or selection bias regarding the lack of body mass index has been mentioned earlier regarding cryptogenic/obese patients. This might have resulted in a lower number of patients in the group of NAFLD reported in our study. Finally, combination of different etiologies (*e.g*., alcoholic liver disease plus chronic HCV) was not considered in order to include the main factor of chronic liver disease.

In conclusion, NAFLD related HCC has been recognized as a growing burden in the United States and in some European regions. This changing etiologic scenario has been observed in in high-income countries and might even be happening in developing ones. In Argentina, even though HCV infection is still the main cause of HCC, recent changing trends in etiologies of HCC in Argentina suggests that NAFLD might be the leading cause of HCC in the next years, becoming an important Public Health issue. However, prospective studies will be necessary to confirm our findings.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The incidence of Hepatocellular carcinoma (HCC) has been increasing during the last years and is the second leading cause of cancer related death worldwide. The cause of HCC is closely linked to the prevalence of chronic hepatitis C (HCV) or B virus (HBV) infections as well as the prevalence of alcoholic liver disease. With the advent of the new direct antiviral drugs (DAAs) for hepatitis C (HCV) treatment, epidemiological changes have been already reported in the natural history of liver disease. One of these epidemiological changes in developed countries is due to the stepwise increase in the incidence of non-alcoholic fatty liver disease (NAFLD), an emergent cause of end stage liver disease and HCC.

Research motivation
-------------------

Indeed, it is estimated that during the next 20 years, non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, will constitute the most frequent cause of cirrhosis and HCC in developed countries. However, reports regarding epidemiological changes of HCC from developing areas, including South America, have been heterogeneous and none have focused on changing trends in etiologies of HCC over time.

Research objectives
-------------------

Our aim was to evaluate changes in the etiology of HCC in Argentina during the last seven years, particularly focusing on potential changes associated with NAFLD-HCC.

Research methods
----------------

This cohort study was conducted between January 1 2009 and January 1 2016 in 14 regional hospitals from Argentina. Criteria for inclusion required patients with newly diagnosed HCC as recommended by international guidelines. Etiologies of HCC included viral hepatitis, alcoholic liver disease (alcohol intake exceeding 30 g/d), NAFLD, cryptogenic cirrhosis (CC), cholestatic liver diseases (*i.e*., primary biliary cholangitis, primary and secondary sclerosing cholangitis), autoimmune hepatitis and other causes including metabolic diseases or miscellaneous causes (*e.g*., hereditary hemochromatosis, Wilson disease, toxic liver disease). NAFLD diagnosis was established on histological ground or clinically according to international guidelines. Baseline patient and tumor characteristics at HCC diagnosis were recorded. Tumor burden was classified according to Barcelona Clinic Liver Cancer staging (BCLC criteria). Complete patient follow-up was assessed in all included subjects from HCC diagnosis until death or last medical visit.

Categorical data were compared using Fisher's exact test (2-tailed) or Chi-Square test and continuous variables were compared with Student's *t*-test or Mann-Whitney *U* test according to their distribution, respectively. For survival analysis, Cox regression multivariate analysis estimating hazard ratios (HR) and 95%CI for baseline variables related with 5-year mortality was performed. Kaplan Meier survival curves were compared using the log-rank test.

Research results
----------------

A total of 708 consecutive adult patients with newly diagnosed HCC from 14 centers were included. Out of 14 hospitals, 6 were LT centers, which contributed with the follow-up of 484 patients (68.4% of the study cohort). Non-cirrhotic patients accounted for 12.6% of the included cohort (*n* = 89). The prevalence of diabetes mellitus (DBT) was 27.7%. Between 2009 and 2016, HCV related HCC was the most frequent etiology along the whole observation period. No significant changes were observed in the proportion of HCV-HCC. The second most frequent cause of HCC was alcoholic liver disease, remaining stable along the observation period. On the other hand, a striking 6-fold increase in the proportion of HCC-NAFLD cases was observed since 2009 to 2016 (4.3% *vs* 25.6%; *P* \< 0.0001). NAFLD was the second cause of HCC in 2015 together with alcoholic liver disease. In addition, when patients with cryptogenic cirrhosis/liver disease and DBT (*n* = 22/68) were considered together as potentially metabolic syndrome/NAFLD, the NAFLD/Cryptogenic + DBT group represented 14.5% (*n* = 103) of the entire cohort and increased from 8.6% in 2009 to 16.2% in 2014 and 25.6% in 2016, respectively (*P* = 0.014). There was a higher prevalence of diabetes mellitus (DBT) (61.7% *vs* non-NAFLD 23.3%; *P* \< 0.0001) in the NAFLD group. The increasing proportion of NAFLD in the overall cohort was not in parallel with an increase of DBT in this population. On the other hand, lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups (6.6 ng/mL *vs* 26 ng/mL; *P =* 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.

Research conclusions
--------------------

To the best of our knowledge this is the first multicenter cohort study from a South American country evaluating longitudinal changes in etiologic trends. This changing etiologic scenario documented in developed countries is replicated in developing ones. The documented increase in NAFLD-HCC in our study including a developing country entails in itself a challenging impact on Public Health worth to be considered. HCV infection was the main etiology of HCC throughout the entire observation period, including the last two years, at which time DAA's therapy was available in Argentina. Second, as reported in other regions of the world, fatty liver disease was observed as an increasing cause of HCC. The prevalence of DBT was significantly higher in NAFLD-HCC when compared to non-NAFLD patients. Finally, NAFLD-HCC was not associated with an increasing risk of mortality, adjusted for the presence HCC surveillance and BCLC stage. NAFLD has been related to an increasing rate of overall cardiovascular morbid-mortality. Consequently, NAFLD will become responsible of an increase in medical resource use in the next years that demands specific health prevention programs focusing in diet and exercise in order to avoid not only liver but also cardiovascular disease development. As previously mentioned, a six-fold increase in NAFLD from 2009 to 2015 was observed in our cohort, mainly in LT centers whereas alcoholic liver disease was a leading cause of HCC in non-LT centers.

Research perspectives
---------------------

NAFLD related HCC has been recognized as a growing burden in the United States and some European regions. This etiologic scenario is not only changing in high-income countries but also it might be happening in developing ones. In Argentina, even though HCV infection is still the main cause of HCC, recent changing trends in etiology of HCC in Argentina suggests that NAFLD might be the leading HCC cause in the next years, becoming an important Public Health issue.
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